• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    6/6/23 9:06:46 AM ET
    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BIAF alert in real time by email

    Gainers

    • Hoth Therapeutics (NASDAQ:HOTH) shares rose 99.5% to $3.75 during Tuesday's pre-market session. The company's market cap stands at $12.3 million.
    • Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 22.15% to $0.15. The market value of their outstanding shares is at $22.3 million.
    • T2 Biosystems (NASDAQ:TTOO) stock increased by 18.14% to $0.08. The market value of their outstanding shares is at $2.0 million.
    • Medigus (NASDAQ:MDGS) stock rose 16.61% to $5.14. The company's market cap stands at $8.4 million.
    • Zura Bio (NASDAQ:ZURA) shares rose 15.55% to $7.5. The company's market cap stands at $238.5 million.
    • PDS Biotechnology (NASDAQ:PDSB) shares increased by 13.16% to $7.39. The market value of their outstanding shares is at $227.7 million.

    Losers

    • HTG Molecular Diagnostics (NASDAQ:HTGM) shares decreased by 41.0% to $0.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $2.1 million.
    • Timber Pharmaceuticals (AMEX:TMBR) shares fell 11.71% to $1.66. The market value of their outstanding shares is at $5.0 million.
    • Pluri (NASDAQ:PLUR) stock declined by 8.59% to $0.73. The company's market cap stands at $30.0 million.
    • bioAffinity Technologies (NASDAQ:BIAF) shares fell 8.07% to $1.71. The company's market cap stands at $14.5 million.
    • INVO Bioscience (NASDAQ:INVO) shares fell 7.95% to $0.18. The market value of their outstanding shares is at $2.5 million.
    • Evaxion Biotech (NASDAQ:EVAX) stock fell 7.85% to $1.41. The company's market cap stands at $37.2 million. As per the news, the Q1 earnings report came out 4 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIAF alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIAF
    $EVAX
    $HOTH
    $HTGM

    CompanyDatePrice TargetRatingAnalyst
    Evaxion A/S
    $EVAX
    2/19/2026$10.00Buy
    Maxim Group
    Zura Bio Limited
    $ZURA
    2/9/2026$15.00Outperform
    Wedbush
    Zura Bio Limited
    $ZURA
    11/4/2024$15.00Outperform
    Leerink Partners
    Zura Bio Limited
    $ZURA
    9/5/2024$5.00Neutral
    H.C. Wainwright
    Zura Bio Limited
    $ZURA
    5/3/2024$26.00Overweight
    Piper Sandler
    Evaxion A/S
    $EVAX
    4/2/2024$8.00Neutral → Buy
    Ladenburg Thalmann
    Evaxion A/S
    $EVAX
    2/12/2024$14.00Buy
    H.C. Wainwright
    Zura Bio Limited
    $ZURA
    10/10/2023$10.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

    Zura Bio Limited (NASDAQ:ZURA) ("Zura"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026. The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of th

    2/27/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer Test

    Validating sample collection by deep suction has potential to accelerate and expand adoption of CyPath® Lung bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a new study with Brooke Army Medical Center (BAMC) to validate the clinical utility of using the CyPath® Lung diagnostic test to assess sputum samples obtained by tracheal and bronchial suctioning for early detection of lung cancer. The study is designed to enroll approximately 30-50 patients undergoing routine tracheal or bronchial suctioning, with results from the study expected by mid-year 2026. Validating the performance

    2/25/26 8:30:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants

    Zura Bio Limited (NASDAQ:ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,800,000 Class A ordinary shares at a price to the public of $6.249 per pre-funded warrant, which equals the public offering price per Class A ordinary share, less the $0.001 exercise price o

    2/25/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manieu Alexandre Weinstein was granted 10,250 shares, exercised 1,002,169 shares at a strike of $0.00 and bought $2,086,956 worth of shares (452,702 units at $4.61) (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    11/20/25 11:35:50 AM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Manieu Alexandre Weinstein bought $4,500,001 worth of shares (976,139 units at $4.61) and disposed of 976,139 shares (SEC Form 4)

    4 - Pluri Inc. (0001158780) (Issuer)

    7/1/25 4:00:11 PM ET
    $PLUR
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Freitag Gregory Gene bought $25,000 worth of shares (15,060 units at $1.66), increasing direct ownership by 33% to 61,213 units (SEC Form 4)

    4 - PDS Biotechnology Corp (0001472091) (Issuer)

    3/3/25 4:45:42 PM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Evaxion Biotech with a new price target

    Maxim Group initiated coverage of Evaxion Biotech with a rating of Buy and set a new price target of $10.00

    2/19/26 8:24:06 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Wedbush initiated coverage on Zura Bio Limited with a new price target

    Wedbush initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    2/9/26 6:54:14 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Leerink Partners initiated coverage on Zura Bio Limited with a new price target

    Leerink Partners initiated coverage of Zura Bio Limited with a rating of Outperform and set a new price target of $15.00

    11/4/24 7:45:03 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    SEC Filings

    View All

    SEC Form 4 filed by Director Eisner Mark

    4 - Zura Bio Ltd (0001855644) (Issuer)

    2/24/26 9:14:02 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Eisner Mark

    3 - Zura Bio Ltd (0001855644) (Issuer)

    2/24/26 9:12:41 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Thiara Parvinder

    4 - Zura Bio Ltd (0001855644) (Issuer)

    1/27/26 6:45:33 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Evaxion A/S

    6-K - Evaxion A/S (0001828253) (Filer)

    2/27/26 4:45:16 PM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: Zura Bio Limited filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - Zura Bio Ltd (0001855644) (Filer)

    2/26/26 8:42:51 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 424B5 filed by Zura Bio Limited

    424B5 - Zura Bio Ltd (0001855644) (Filer)

    2/25/26 5:06:18 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Leadership Updates

    Live Leadership Updates

    View All

    Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date. "Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a

    2/23/26 6:30:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory Board

    Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans

    2/9/26 8:00:00 AM ET
    $BIAF
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Zura Bio Appoints Immunology Industry Leader Sandeep Kulkarni, M.D. as Chief Executive Officer

    Zura Bio Limited (NASDAQ:ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointment of Sandeep Kulkarni, M.D. as Chief Executive Officer (CEO), effective January 21, 2026. Dr. Kulkarni will also continue serving as a Director of Zura. Dr. Kulkarni succeeds Kim Davis, J.D., who has served as Interim CEO since October 2025 following the commencement of a medical leave of absence by CEO Robert Lisicki. Mr. Lisicki is resigning as CEO and as a Director, effective as of January 21, 2026. Ms.

    1/21/26 8:50:00 AM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Financials

    Live finance-specific insights

    View All

    PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update

    Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer Phase 2 Results Lead Company to Seek Expedited Approval Pathway in OngoingVERSATILE-003 Phase 3 Trial Design Conference Call and Webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update, reported financial results for the third quarter ended September 30, 2025, and provided a clinical program

    11/13/25 7:30:00 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results

    PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2025 and provide a clinical programs update on Thursday, November 13, 2025 at 8:00 am Eastern Time. Conference Call Details Date: November 13, 2025Time: 8:00 a.m. Eastern TimeDial-in: 1-877-704-4453 (Domestic) or 1-201-389-0920 (International) Webcast Registration: Click HereCall MeTM Registration: Click Here (Available 15 minutes p

    11/6/25 8:00:00 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

    Correcting press release issued under same heading: Date in body text corrected to "November 6, 2025" as in headline. COPENHAGEN, Denmark, October 31, 2025 - Evaxion A/S (NASDAQ:EVAX) ("Evaxion"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2025 financial results on Thursday November 6, 2025, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged. To join the conference call, listen

    10/31/25 9:05:34 AM ET
    $EVAX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $BIAF
    $EVAX
    $HOTH
    $HTGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:52:59 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Zura Bio Limited

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 5:06:21 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Zura Bio Limited

    SC 13G - Zura Bio Ltd (0001855644) (Subject)

    11/14/24 4:47:14 PM ET
    $ZURA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care